IP Library Patent Application 13657976
Patent Application
App. No. 13/657,976

Antimicrobial Molecules For Treating Multi-Drug Resistant and Extensively Drug Resistant Strains Of Mycobacterium

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/657,976
Abstract

The present invention provides methods of inhibiting the growth of Mycobacterium species or treating an animal having a Mycobacterium infection (including multi-drug resistance strains and extensively drug resistant strains) by administering a compound of the invention, a salt thereof, or a composition comprising the same.

Claims (48)

1 . A method of inhibiting the growth of a Mycobacterium species comprising contacting the Mycobacterium species with an effective amount of a compound or salt thereof, wherein the compound or salt thereof is selected from:

a) a compound of Formula I:

or salt thereof, wherein R 1 is H or C 1-10 alkyl; R 2 is H or C 1-10 alkyl; and m is 1 or 2;

b) a compound of Formula II:

or salt thereof, wherein R 3 is H or C 1-10 alkyl; and R 4 is H or C 1-10 alkyl; and

c) a compound of Formula III:

or salt thereof, wherein R 5 is H or C 1-10 alkyl; and R 6 is H or C 1-10 alkyl.

2 . The method of claim 1 wherein the compound or salt thereof is a compound of Formula I or salt thereof.

3 . The method of claim 2 wherein the compound of Formula I or salt thereof is a compound of Formula Ia:

or salt thereof, wherein R 1 is H or C 1-8 alkyl; and R 2 is H or C 1-8 alkyl.

4 - 7 . (canceled)

8 . The method of claim 2 wherein the compound of Formula I or salt thereof is a compound of Formula Ib:

or salt thereof, wherein R 1 is H or C 1-10 alkyl; and R 2 is H or C 1-10 alkyl.

9 - 12 . (canceled)

13 . The method of claim 1 wherein the compound or salt thereof is a compound of Formula II or salt thereof.

14 - 16 . (canceled)

17 . The method of claim 1 wherein the compound or salt thereof is a compound of Formula III or salt thereof.

18 - 20 . (canceled)

21 . The method of claim 1 wherein the compound or salt thereof is a compound selected from:

or a salt thereof.

22 . The method of claim 1 wherein the Mycobacterium species is Mycobacterium Tuberculosis.

23 . The method of claim 22 wherein the Mycobacterium Tuberculosis is a multi-drug resistant strain.

24 . The method of claim 22 wherein the Mycobacterium Tuberculosis is an extensively drug resistant strain.

25 . A method of treating an animal having a Mycobacterium infection comprising administering to the animal a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutically acceptable salt thereof is selected from:

a) a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein R 1 is H or C 1-10 alkyl; R 2 is H or C 1-10 alkyl; and m is 1 or 2;

b) a compound of Formula II:

or a pharmaceutically acceptable salt thereof, wherein R 3 is H or C 1-10 alkyl; and R 4 is H or C 1-10 alkyl; and

c) a compound of Formula III:

or a pharmaceutically acceptable salt thereof, wherein R 5 is H or C 1-10 alkyl; and R 6 is H or C 1-10 alkyl.

26 . The method of claim 25 wherein the compound or pharmaceutically acceptable salt thereof is a compound of Formula I or a pharmaceutically acceptable salt thereof.

27 . The method of claim 26 wherein the compound of Formula I or pharmaceutically acceptable salt thereof is a compound of Formula Ia:

or a pharmaceutically acceptable salt thereof, wherein R 1 is H or C 1-8 alkyl; R 2 is H or C 1-8 alkyl.

28 - 31 . (canceled)

32 . The method of claim 26 wherein the compound of Formula I or pharmaceutically acceptable salt thereof is a compound of Formula Ib:

or pharmaceutically acceptable salt thereof, wherein R 1 is H or C 1-10 alkyl; and R 2 is H or C 1-10 alkyl.

33 - 36 . (canceled)

37 . The method of claim 25 wherein the compound or pharmaceutically acceptable salt thereof is a compound of Formula II or pharmaceutically acceptable salt thereof.

38 - 40 . (canceled)

41 . The method of claim 25 wherein the compound or pharmaceutically acceptable salt thereof is a compound of Formula III or pharmaceutically acceptable salt thereof.

42 - 44 . (canceled)

45 . The method of claim 25 wherein the compound or pharmaceutically acceptable salt thereof is a compound selected from:

or a pharmaceutically acceptable salt thereof.

46 . The method of claim 25 wherein the Mycobacterium infection is Mycobacterium Tuberculosis.

47 . The method of claim 46 wherein the Mycobacterium Tuberculosis is a multi-drug resistant strain.

48 . The method of claim 46 wherein the Mycobacterium Tuberculosis is an extensively drug resistant strain.

49 . The method of claim 1 wherein the compound or salt thereof is present in a composition.

50 - 52 . (canceled)

Assignments (3)
BANKRUPTCY COURT ORDER/ASSET PURCHASE AGREEMENT Recorded Nov 12, 2013
From: POLYMEDIX, INC.
To: CELLCEUTIX CORPORATION
Reel/Frame 031626/0240 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2013
From: SCOTT, RICHARD W.; LIU, DAHUI
To: POLYMEDIX, INC.
Reel/Frame 029791/0329 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 17, 2013
From: POLYMEDIX, INC.; POLYMEDIX PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 029660/0322 →